Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
P/B ratio for Adial Pharmaceuticals, Inc. (ADIL)
P/B ratio as of 2023: 0.65
According to Adial Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.65. At the end of 2022 the company had a P/B ratio of 0.07.
P/B ratio history for Adial Pharmaceuticals, Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.65 |
| 2022 | 0.07 |
| 2021 | 14.31 |
| 2020 | 5.32 |
| 2019 | 3.33 |
| 2018 | 5.49 |
| 2017 | -22.23 |
| 2016 | -186.99 |
| 2015 | 118.71 |